MAPT and Alzheimer disease: The main finding of our study is that endorsement of (multiple) SCD‐plus features appears to be a robust indicator of abnormally elevated AD biomarker levels in CU older adults, with more frequent endorsement in participants with preclinical AD (community‐based only) and significant associations with Aβ and/or tau pathology burden.